Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsInvestigators used proximity labeling to identify protein interactors of active KRAS in pancreatic ductal adenocarcinoma (PDAC) cells. We expressed fusions of wild-type (WT) (BirA-KRAS4B), mutant (BirA-KRAS4BG12D), and nontransforming cytosolic double mutant (BirA-KRAS4BG12D/C185S) KRAS with the BirA biotin ligase in murine PDAC cells.
[Proceedings of the National Academy of Sciences of the United States of America]
7753456 TQHXVBP4 items 1 apa 0 default asc 1 162575 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-0fbf8ec1f6424480529c3aa6eec20765%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22TQHXVBP4%22%2C%22library%22%3A%7B%22id%22%3A7753456%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cheng%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECheng%2C%20D.%20K.%2C%20Oni%2C%20T.%20E.%2C%20Thalappillil%2C%20J.%20S.%2C%20Park%2C%20Y.%2C%20Ting%2C%20H.-C.%2C%20Alagesan%2C%20B.%2C%20Prasad%2C%20N.%20V.%2C%20Addison%2C%20K.%2C%20Rivera%2C%20K.%20D.%2C%20Pappin%2C%20D.%20J.%2C%20Aelst%2C%20L.%20V.%2C%20%26amp%3B%20Tuveson%2C%20D.%20A.%20%282021%29.%20Oncogenic%20KRAS%20engages%20an%20RSK1%5C%2FNF1%20pathway%20to%20inhibit%20wild-type%20RAS%20signaling%20in%20pancreatic%20cancer.%20%3Ci%3EProceedings%20of%20the%20National%20Academy%20of%20Sciences%3C%5C%2Fi%3E%2C%20%3Ci%3E118%3C%5C%2Fi%3E%2821%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.2016904118%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.2016904118%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D7753456%26amp%3Bitem_key%3DTQHXVBP4%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Oncogenic%20KRAS%20engages%20an%20RSK1%5C%2FNF1%20pathway%20to%20inhibit%20wild-type%20RAS%20signaling%20in%20pancreatic%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derek%20K.%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobiloba%20E.%22%2C%22lastName%22%3A%22Oni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20S.%22%2C%22lastName%22%3A%22Thalappillil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Youngkyu%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hsiu-Chi%22%2C%22lastName%22%3A%22Ting%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brinda%22%2C%22lastName%22%3A%22Alagesan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%20V.%22%2C%22lastName%22%3A%22Prasad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%22%2C%22lastName%22%3A%22Addison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20D.%22%2C%22lastName%22%3A%22Rivera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darryl%20J.%22%2C%22lastName%22%3A%22Pappin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%20Van%22%2C%22lastName%22%3A%22Aelst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Tuveson%22%7D%5D%2C%22abstractNote%22%3A%22Pancreatic%20ductal%20adenocarcinoma%20%28PDAC%29%20is%20a%20lethal%20malignancy%20with%20limited%20treatment%20options.%20Although%20activating%20mutations%20of%20the%20KRAS%20GTPase%20are%20the%20predominant%20dependency%20present%20in%20%3E90%25%20of%20PDAC%20patients%2C%20targeting%20KRAS%20mutants%20directly%20has%20been%20challenging%20in%20PDAC.%20Similarly%2C%20strategies%20targeting%20known%20KRAS%20downstream%20effectors%20have%20had%20limited%20clinical%20success%20due%20to%20feedback%20mechanisms%2C%20alternate%20pathways%2C%20and%20dose-limiting%20toxicities%20in%20normal%20tissues.%20Therefore%2C%20identifying%20additional%20functionally%20relevant%20KRAS%20interactions%20in%20PDAC%20may%20allow%20for%20a%20better%20understanding%20of%20feedback%20mechanisms%20and%20unveil%20potential%20therapeutic%20targets.%20Here%2C%20we%20used%20proximity%20labeling%20to%20identify%20protein%20interactors%20of%20active%20KRAS%20in%20PDAC%20cells.%20We%20expressed%20fusions%20of%20wild-type%20%28WT%29%20%28BirA-KRAS4B%29%2C%20mutant%20%28BirA-KRAS4BG12D%29%2C%20and%20nontransforming%20cytosolic%20double%20mutant%20%28BirA-KRAS4BG12D%5C%2FC185S%29%20KRAS%20with%20the%20BirA%20biotin%20ligase%20in%20murine%20PDAC%20cells.%20Mass%20spectrometry%20analysis%20revealed%20that%20RSK1%20selectively%20interacts%20with%20membrane-bound%20KRASG12D%2C%20and%20we%20demonstrate%20that%20this%20interaction%20requires%20NF1%20and%20SPRED2.%20We%20find%20that%20membrane%20RSK1%20mediates%20negative%20feedback%20on%20WT%20RAS%20signaling%20and%20impedes%20the%20proliferation%20of%20pancreatic%20cancer%20cells%20upon%20the%20ablation%20of%20mutant%20KRAS.%20Our%20findings%20link%20NF1%20to%20the%20membrane-localized%20functions%20of%20RSK1%20and%20highlight%20a%20role%20for%20WT%20RAS%20signaling%20in%20promoting%20adaptive%20resistance%20to%20mutant%20KRAS-specific%20inhibitors%20in%20PDAC.%22%2C%22date%22%3A%222021%5C%2F05%5C%2F25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1073%5C%2Fpnas.2016904118%22%2C%22ISSN%22%3A%220027-8424%2C%201091-6490%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.pnas.org%5C%2Fcontent%5C%2F118%5C%2F21%5C%2Fe2016904118%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%223XSKJF5U%22%5D%2C%22dateModified%22%3A%222021-05-25T17%3A15%3A07Z%22%7D%7D%5D%7D
Cheng, D. K., Oni, T. E., Thalappillil, J. S., Park, Y., Ting, H.-C., Alagesan, B., Prasad, N. V., Addison, K., Rivera, K. D., Pappin, D. J., Aelst, L. V., & Tuveson, D. A. (2021). Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proceedings of the National Academy of Sciences, 118(21). https://doi.org/10.1073/pnas.2016904118 Cite
